



BIODIEM LTD
ABN 20 096 845 993

Level 4,
100, Albert Road,
South Melbourne, Victoria, 3205
Australia

Phone: +61 3 9692 7240
Web: www.biodiem.com

22 January 2016

COMPLETION OF NON-RENOUNCEABLE ENTITLEMENT OFFER AND ISSUE OF ENTITLEMENT AND SHORTFALL SHARES

BioDiem Limited ("BioDiem" or "the Company") advises that it has now completed the issue and allotment of entitlement and shortfall shares under the shortfall facility of its recent Non-Renounceable Entitlement Offer.

As notified previously to shareholders, two of BioDiem's largest shareholders received shares prior to the rights issue and then did not take up their own entitlements under the Offer. The shares they received were under the same terms as those under the rights issue Offer. BioDiem confirms that it has raised a total of \$290,973 under the Entitlement Offer. A breakdown of the number of shares issued and funds raised under the respective components of the Entitlement Offer (the entitlement component and shortfall facility component) is as follows:

	NO. OF SHARES	SUBSCRIPTION FUNDS
Application for entitlement shares	471,844	\$37,747.52
Applications for additional shares under shortfall facility	3,165,322	\$253,225.76
Total applications under Offer	3,637,166	\$290,973.28
Placement to major shareholders prior to rights issue Offer	3,735,250	\$298,820.00
Total funds received from placement and Offer	7,372,416	\$589,793.28

Effect of Rights Issue on Capital Structure

The Company confirms that following allotment of the entitlement and shortfall shares under the Entitlement Offer, BioDiem has 174,734,060 fully paid ordinary shares on issue. A current statement setting out the names of the 20 largest holders of fully paid ordinary shares and percentage held by each is attached. A table showing the Company's current capital structure is set out below.

EVENT	NO. OF SHARES
Shares on issue before rights issue	171,096,894
Entitlement shares issued under the rights issue	471,844
Additional shares issued under shortfall facility	3,165,322
Total shares issue under rights issue	3,637,166
Total shares on issue after completion of the rights issue	174,734,060

Additional Shares

As previously announced on 22 December 2015, the Company advised that it received applications for shortfall shares.

In summary, all shortfall applications were accepted in full and no scale back was undertaken. In accordance with the entitlement offer prospectus, the Company had discretion regarding the allocation of the shortfall Shares to applicants.

No allocation was made to the extent that the allocation would result in the holder obtaining a relevant interest of greater than 20% of the post offer total fully paid ordinary shares in the Company.

All shareholders who accepted their full entitlement being issued 1 share for every 18 shares held at the Record Date were issued.

Confirmation of the number of shares issued will be sent to applicants.

Remaining Shortfall Shares

Under the Entitlement offer prospectus dated 17 November 2015, the maximum amount of shares that could be issued was 5,592,482. A total of 3,637,166 shares have been issued under the prospectus to date, leaving a shortfall of 1,955,316 shares.

Under the terms of the Entitlement offer prospectus the Directors have discretion in the allocation of shortfall shares to applicants and may reject an application for shortfall Shares or allocate fewer shortfall Shares than applied for. The Company also retains the discretion to accept late acceptances or applications.

Under the terms of the Entitlement offer prospectus no shares will be issued on the basis of this Prospectus after the expiry date of the Prospectus being 13 months after the date of the Prospectus.

The Company welcomes enquiries by interested parties wishing to apply for the remaining shortfall shares.

Yours faithfully,



Julie Phillips

Chief Executive Officer

BioDiem Ltd

Phone + 61 3 9692 7240

Email jphillips@biodiem.com